<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04143191</url>
  </required_header>
  <id_info>
    <org_study_id>FAH-20190358</org_study_id>
    <nct_id>NCT04143191</nct_id>
  </id_info>
  <brief_title>Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCC</brief_title>
  <acronym>SOURCE</acronym>
  <official_title>Sorafenib Plus Transarterial Chemoembolization Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced Hepatocellular Carcinoma: A Phase 3, Multicenter, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a multi-center, phase III, randomized (1:1) clinical trial. The aim is to
      explore the efficacy and safety of Sorafenib combined with transarterial chemoembolization as
      adjuvant treatment for resectable advanced hepatocellular carcinoma, compared with Sorafenib
      alone. The primary endpoint is recurrence-free survival. This trial planned to recruit 158
      patients who received curative hepatic resection with resectable advanced hepatocellular
      carcinoma. The patients will be randomized into Sorafenib group and Sorafenib+TACE group as
      1:1 ratio.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2019</start_date>
  <completion_date type="Anticipated">September 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>Recurrence-free survival indicates the interval between randomization and tumor recurrence or death.[0-2 years] Longer RFS time indicates better prognosis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>Overall survival indicates the interval between randomization and death.[0-2years]Longer OS time indicates better prognosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence</measure>
    <time_frame>2 years</time_frame>
    <description>Time to recurrence indicates the interval between randomization and tumor recurrence.[0-2years]Longer TTR time indicates better prognosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence rate of severe adverse events. [0-100%]. lower rate indicates more safety of the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>2 years</time_frame>
    <description>Questionnaire score of EORTC-QOL. Higher score indicates better quality of life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">158</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Sorafenib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm will take Sorafenib orally with the dose of 400mg bid on the third day after randomization till recurrence or the end of this trial. If any drug related adverse event occurred, the dosage will be reduced.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sorafenib plus TACE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will take Sorafenib orally with the dose of 400mg bid on the third day after randomization till recurrence or the end of this trial. TACE will be performed on the fourth day after randomization. If any drug related adverse event occurred, the dosage will be reduced.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Sorafenib is one of tyrosine kinase inhibitors. The initial dosage is 400mg orally, twice daily.</description>
    <arm_group_label>Sorafenib</arm_group_label>
    <arm_group_label>Sorafenib plus TACE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transarterial chemoembolization</intervention_name>
    <description>TACE including conventional TACE (cTACE) and DEB-TACE. Treatment choices are according to the specific condition of each patient and the experience of interventional radiologists.</description>
    <arm_group_label>Sorafenib plus TACE</arm_group_label>
    <other_name>TACE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Primary hepatocellular carcinoma without any treatments.

          2. Received curative hepatic resection

          3. ECOG score 0-1

          4. Child-Pugh grade A

          5. Sufficient liver and kidney function

        Exclusion Criteria:

          1. Diffused lesions; tumor thrombosis in SMV or IVC.

          2. Extra-hepatic metastasis.

          3. Contraindication of TACE, like portal-systemic shunt, obvious atherosclerosis, etc.

          4. Allergic to the contrast agent of TACE

          5. Dysfunction of liver, kidney or bone marrow.

          6. Concomitant other malignant tumor or HIV infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ming Kuang, MD, PhD.</last_name>
    <phone>008687755766</phone>
    <phone_ext>8576</phone_ext>
    <email>kuangm@mail.sysu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming Kuang, Ph.D.</last_name>
      <phone>008687755766</phone>
      <phone_ext>8576</phone_ext>
      <email>kuangm@mail.sysu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 26, 2019</study_first_submitted>
  <study_first_submitted_qc>October 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2019</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Ming Kuang</investigator_full_name>
    <investigator_title>Vice-president</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

